Evidence map›Paper›PMID 34406489›Full record

ArticleLangenbeck's archives of surgery2022

Adjuvant transarterial chemotherapy for margin-positive resection of hepatocellular carcinoma-a propensity score matched analysis.

Alvina Jada Fok, Wong Hoi She, Ka Wing Ma, Simon H Y Tsang, Wing Chiu Dai, Albert C Y Chan, Chung Mau Lo, Tan To Cheung

Abstract read
PubMed Publisher
In one paragraph

Article in Langenbeck's archives of surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Alvina Jada FokDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The University of Hong Kong, 102 Pok Fu Lam Road, Hong Kong, China.
Wong Hoi SheDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The University of Hong Kong, 102 Pok Fu Lam Road, Hong Kong, China. shewhbrian@gmail.com.ORCID http://orcid.org/0000-0003-2049-3140
Ka Wing MaDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The University of Hong Kong, 102 Pok Fu Lam Road, Hong Kong, China.
Simon H Y TsangDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The University of Hong Kong, 102 Pok Fu Lam Road, Hong Kong, China.
Wing Chiu DaiDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The University of Hong Kong, 102 Pok Fu Lam Road, Hong Kong, China.
Albert C Y ChanDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The University of Hong Kong, 102 Pok Fu Lam Road, Hong Kong, China.
Chung Mau LoDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The University of Hong Kong, 102 Pok Fu Lam Road, Hong Kong, China.
Tan To CheungDivision of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The University of Hong Kong, 102 Pok Fu Lam Road, Hong Kong, China.
University of Hong Kong · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsHepatectomy is a well-established curative treatment for hepatocellular carcinoma. However, the role of adjuvant therapy is controversial. This study examines the efficacy of adjuvant transarterial chemotherapy for hepatocellular carcinoma.

methodsThe data of hepatocellular carcinoma patients undergoing curative hepatectomy was reviewed. Those with adjuvant transarterial chemotherapy were matched with those without using propensity score analysis, by tumour size and number, indocyanine green retention rate, disease staging and Child-Pugh grading. The groups were compared.

resultsEighty-seven patients with hepatocellular carcinoma who underwent hepatectomy received adjuvant transarterial chemotherapy (TAC group), and were matched with 870 patients who did not (no-TAC group). The groups were largely comparable in patient and disease characteristics, but the TAC group experienced more blood loss, higher transfusion rates, narrower margins and more positive margins. The two groups were found to be comparable in disease-free and overall survival rates. In margin-positive patients, those given TAC survived longer than those without, and margin-positive patients in the TAC group had overall survival rates similar to margin-negative patients in the no-TAC group.

conclusionsMargin involvement is an adverse factor for survival in HCC. Adjuvant transarterial chemotherapy may offer survival benefits to hepatocellular carcinoma patients with positive surgical margins.

Indexed as

Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsChemotherapy, AdjuvantHepatectomyHumansNeoplasm Recurrence, LocalPropensity ScoreRetrospective StudiesAdjuvant therapyHepatectomyHepatocellular carcinomaTransarterial chemotherapy

Identifiers

PMID34406489
OpenAlexW3194258668

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.